Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy) (TA259)
Fast, easy summary view of NICE guidance on 'prostate cancer'
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
NICE recommends abiraterone as a possible treatment for some adults with metastatic prostate cancer who have already had treatment to reduce testosterone and have had docetaxel chemotherapy (see below).
Who can have abiraterone?
You should be able to have abiraterone if you’ve had docetaxel chemotherapy but your disease has stopped responding to treatment.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life. NICE recommended abiraterone because it works better than other treatments available on the NHS. Although it also costs more than other treatments, this was justified by the benefits it provided when the special considerations were applied.
- TA259 Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): guidance (web format)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: prostate cancer
This page was last updated: 15 October 2012
Information for the public
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.